Biologic Therapy Market to record USD 226.61 Bn growth -- North America to account for 57% market share

News provided by

Sep 19, 2022, 01:00 ET

NEW YORK, Sept. 19, 2022 /PRNewswire/ -- The "Biologic Therapeutics Market by Product and Geography - Forecast and Analysis 2021-2025" report has been added to Technavio's offering. The report expects the market size to grow by USD 226.61 billion between 2021 and 2026, accelerating at a CAGR of 11% during the forecast period. The report provides a comprehensive analysis of the competitive landscape, key product launches, major trends, and other important statistics. Download PDF Sample Report

Market Dynamics

Technavio has announced its latest market research report titled Global Biologic Therapy Market

The market is primarily driven by factors such as the strong R&D pipeline. In addition, the increasing incidence of chronic diseases and immunological disorders will have a positive impact on the growth of the market. However, the high cost of biologics is expected to reduce the growth potential in the market.

Market Segmentation

By Product, the market is classified into antibody therapeutics, vaccines, cell therapy, gene therapy, and other therapies. The antibody therapeutics segment is the largest segment of the global biologic therapy market. The market will observe maximum revenue generation in the antibody therapies segment during the forecast period. The segment is driven by the increasing demand and sales of antibodies in the pharmaceutical industry.
By Geography, the market is classified as North America, Europe, Asia, and ROW. North America will have the largest share of the market. The region is home to several key vendors such as AbbVie, Elli Lilly, Merck, Pfizer, and Amgen. Besides, changes in lifestyle and increased consumption of alcohol and tobacco have increased the prevalence of various chronic diseases. In addition, the active participation of the government in providing reimbursements for some of the biologics, rising patient awareness about the benefits of the use of biologics, vendor collaborations, and the increased prevalence of chronic diseases in the US are contributing to the growth of the biologic therapeutics market in North America.

Company Profiles

The biologic therapy market report provides complete insights on key vendors including AbbVie Inc., AstraZeneca Plc, Bristol-Myers Squibb Co., F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Johnson and Johnson Inc., Merck and Co. Inc., Novartis AG, Pfizer Inc., and Sanofi SA.

Competitive Analysis

The global biologic therapeutics market is concentrated. The vendors are adopting organic and inorganic growth strategies such as new product launches and M&As to remain competitive in the market. For instance, in June 2020, AbbVie Inc. and Jacobio Pharmaceuticals announced a global, strategic collaboration to develop and commercialize SHP2 inhibitors, which target a key node in cancer and immune cells. Similarly, in June 2020, GlaxoSmithKline Plc announced a strategic partnership with IDEAYA Biosciences, Inc., in Synthetic Lethality, an emerging field in oncology.

The competitive scenario provided in the biologic therapy market report analyzes, evaluates, and positions companies based on various performance indicators. Some of the factors considered for this analysis include the financial performance of companies over the past few years, growth strategies, product innovations, new product launches, investments, growth in market share, etc. Request Sample Report Here

Related Reports:

Biologic Therapy Market Scope
Report Coverage	Details
Page number	120
Base year	2020
Forecast period	2021-2025
Growth momentum & CAGR	Accelerate at a CAGR of 11%
Market growth 2021-2025	USD 226.61 billion
Market structure	Concentrated
YoY growth (%)	9.71
Regional analysis	North America, Europe, Asia, and ROW
Performing market contribution	North America at 57%
Key consumer countries	US, Japan, Germany, France, and UK
Competitive landscape	Leading companies, competitive strategies, consumer engagement scope
Companies profiled	AbbVie Inc., AstraZeneca Plc, Bristol-Myers Squibb Co., F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Johnson and Johnson Inc., Merck and Co. Inc., Novartis AG, Pfizer Inc., and Sanofi SA
Market Dynamics	Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and future consumer dynamics, and market condition analysis for the forecast period.
Customization purview	If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Table of contents:

1 Executive Summary

2 Market Landscape

2.1 Market ecosystem

Exhibit 01: Parent market
Exhibit 02: Market characteristics

2.2 Value chain analysis

3 Market Sizing

3.1 Market definition

Exhibit 03: Offerings of vendors included in the market definition

3.2 Market segment analysis

Exhibit 04: Market segments

3.3 Market size 2020

3.4 Market outlook: Forecast for 2020 - 2025

Exhibit 05: Global - Market size and forecast 2020 - 2025 ($ billion)
Exhibit 06: Global market: Year-over-year growth 2020 - 2025 (%)

3.5 Market by application

4 Five Forces Analysis

4.1 Five forces summary

Exhibit 07: Five forces analysis 2020 & 2025

4.2 Bargaining power of buyers

Exhibit 08: Bargaining power of buyers

4.3 Bargaining power of suppliers

Exhibit 09: Bargaining power of suppliers

4.4 Threat of new entrants

Exhibit 10: Threat of new entrants

4.5 Threat of substitutes

Exhibit 11: Threat of substitutes

4.6 Threat of rivalry

Exhibit 12: Threat of rivalry

4.7 Market condition

Exhibit 13: Market condition - Five forces 2020

5 Market Segmentation by Product

5.1 Market segments

Exhibit 14: Product - Market share 2020-2025 (%)

5.2 Comparison by Product

Exhibit 15: Comparison by Product

5.3 Antibody therapeutics - Market size and forecast 2020-2025

Exhibit 16: Antibody therapeutics - Market size and forecast 2020-2025 ($ billion)
Exhibit 17: Sales of major monoclonal antibodies 2018-2020 ($ million)
Exhibit 18: Antibody therapeutics - Year-over-year growth 2020-2025 (%)

5.4 Vaccines - Market size and forecast 2020-2025

Exhibit 19: Vaccines - Market size and forecast 2020-2025 ($ billion)
Exhibit 20: Vendors offering vaccines
Exhibit 21: Vaccines - Year-over-year growth 2020-2025 (%)

5.5 Cell therapy - Market size and forecast 2020-2025

Exhibit 22: Cell therapy - Market size and forecast 2020-2025 ($ billion)
Exhibit 23: Cell therapy - Year-over-year growth 2020-2025 (%)

5.6 Gene therapy - Market size and forecast 2020-2025

Exhibit 24: Gene therapy - Market size and forecast 2020-2025 ($ billion)
Exhibit 25: Gene therapy - Year-over-year growth 2020-2025 (%)

5.7 Other therapies - Market size and forecast 2020-2025

Exhibit 26: Other therapies - Market size and forecast 2020-2025 ($ billion)
Exhibit 27: Other therapies - Year-over-year growth 2020-2025 (%)

5.8 Market opportunity by Product

Exhibit 28: Market opportunity by Product

6 Customer landscape

7 Geographic Landscape

7.1 Geographic segmentation

Exhibit 30: Market share by geography 2020-2025 (%)

7.2 Geographic comparison

Exhibit 31: Geographic comparison

7.3 North America - Market size and forecast 2020-2025

Exhibit 32: North America - Market size and forecast 2020-2025 ($ billion)
Exhibit 33: North America - Year-over-year growth 2020-2025 (%)

7.4 Europe - Market size and forecast 2020-2025

Exhibit 34: Europe - Market size and forecast 2020-2025 ($ billion)
Exhibit 35: Europe - Year-over-year growth 2020-2025 (%)

7.5 Asia - Market size and forecast 2020-2025

Exhibit 36: Asia - Market size and forecast 2020-2025 ($ billion)
Exhibit 37: Asia - Year-over-year growth 2020-2025 (%)

7.6 ROW - Market size and forecast 2020-2025

Exhibit 38: ROW - Market size and forecast 2020-2025 ($ billion)
Exhibit 39: ROW - Year-over-year growth 2020-2025 (%)

7.7 Key leading countries

Exhibit 40: Key leading countries

7.8 Market opportunity by geography

Exhibit 41: Market opportunity by geography ($ billion)

8 Drivers, Challenges, and Trends

8.1 Market drivers

8.2 Market challenges

Exhibit 43: Impact of drivers and challenges

8.3 Market trends

9 Vendor Landscape

9.1 Overview

Exhibit 44: Vendor landscape

9.2 Landscape disruption

Exhibit 45: Landscape disruption
Exhibit 46: Industry risks

10 Vendor Analysis

10.1 Vendors covered

Exhibit 47: Vendors covered

10.2 Market positioning of vendors

Exhibit 48: Market positioning of vendors

10.3 AbbVie Inc.

Exhibit 49: AbbVie Inc. - Overview
Exhibit 50: AbbVie Inc. - Product and service
Exhibit 51: AbbVie Inc. – Key news
Exhibit 52: AbbVie Inc. - Key offerings

10.4 AstraZeneca Plc

Exhibit 53: AstraZeneca Plc - Overview
Exhibit 54: AstraZeneca Plc - Product and service
Exhibit 55: AstraZeneca Plc – Key news
Exhibit 56: AstraZeneca Plc - Key offerings

10.5 Bristol-Myers Squibb Co.

Exhibit 57: Bristol-Myers Squibb Co. - Overview
Exhibit 58: Bristol-Myers Squibb Co. - Product and service
Exhibit 59: Bristol-Myers Squibb Co. – Key news
Exhibit 60: Bristol-Myers Squibb Co. - Key offerings

10.6 F. Hoffmann-La Roche Ltd.

Exhibit 61: F. Hoffmann-La Roche Ltd. - Overview
Exhibit 62: F. Hoffmann-La Roche Ltd. - Business segments
Exhibit 63: F. Hoffmann-La Roche Ltd. – Key news
Exhibit 64: F. Hoffmann-La Roche Ltd. - Key offerings
Exhibit 65: F. Hoffmann-La Roche Ltd. - Segment focus

10.7 GlaxoSmithKline Plc

Exhibit 66: GlaxoSmithKline Plc - Overview
Exhibit 67: GlaxoSmithKline Plc - Business segments
Exhibit 68: GlaxoSmithKline Plc – Key news
Exhibit 69: GlaxoSmithKline Plc - Key offerings
Exhibit 70: GlaxoSmithKline Plc - Segment focus

10.8 Johnson and Johnson Inc.

Exhibit 71: Johnson and Johnson Inc. - Overview
Exhibit 72: Johnson and Johnson Inc. - Business segments
Exhibit 73: Johnson and Johnson Inc. – Key news
Exhibit 74: Johnson and Johnson Inc. - Key offerings
Exhibit 75: Johnson and Johnson Inc. - Segment focus

10.9 Merck and Co. Inc.

Exhibit 76: Merck and Co. Inc. - Overview
Exhibit 77: Merck and Co. Inc. - Business segments
Exhibit 78: Merck and Co. Inc. – Key news
Exhibit 79: Merck and Co. Inc. - Key offerings
Exhibit 80: Merck and Co. Inc. - Segment focus

10.10 Novartis AG

Exhibit 81: Novartis AG - Overview
Exhibit 82: Novartis AG - Business segments
Exhibit 83: Novartis AG – Key news
Exhibit 84: Novartis AG - Key offerings
Exhibit 85: Novartis AG - Segment focus

10.11 Pfizer Inc.

Exhibit 86: Pfizer Inc. - Overview
Exhibit 87: Pfizer Inc. - Business segments
Exhibit 88: Pfizer Inc. – Key news
Exhibit 89: Pfizer Inc. - Key offerings

10.12 Sanofi SA

Exhibit 90: Sanofi SA - Overview
Exhibit 91: Sanofi SA - Business segments
Exhibit 92: Sanofi SA – Key news
Exhibit 93: Sanofi SA - Key offerings
Exhibit 94: Sanofi SA - Segment focus

11 Appendix

11.1 Scope of the report

11.2 Currency conversion rates for US$

Exhibit 95: Currency conversion rates for US$

11.3 Research methodology

Exhibit 96: Research Methodology
Exhibit 97: Validation techniques employed for market sizing
Exhibit 98: Information sources

11.4 List of abbreviations

Exhibit 99: List of abbreviations

About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contact

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/

SOURCE Technavio